Pulmonx (LUNG) Stock Price, News & Analysis

Company Overview

Pulmonx Corporation is a medical technology company focused on developing and commercializing minimally invasive treatments for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its products are designed to reduce hyperinflation in damaged portions of the lungs and improve breathing without requiring surgical lung-volume-reduction procedures.

The company’s primary product is the Zephyr Endobronchial Valve, a small, one-way valve placed in the airways using a bronchoscope. The valve allows trapped air to exit diseased areas of the lung while limiting the entry of new air, which may enable healthier portions of the lung to function more effectively. Pulmonx also offers the Chartis Pulmonary Assessment System, a diagnostic tool used to evaluate collateral ventilation and help physicians determine whether a patient may be an appropriate candidate for Zephyr Valve treatment.

Pulmonx serves hospitals, physicians and patients in the United States and international markets through a combination of direct commercial operations and distribution partners. The Zephyr Valve received authorization for use in the United States from the U.S. Food and Drug Administration in 2018, and the company has expanded its commercial presence in Europe and other global markets. Pulmonx is headquartered in Redwood City, California, and its common stock trades on the Nasdaq under the symbol LUNG.

Key Stats

• Today's Range: $1.99 to $2.08
• 50-Day Range: $1.17 to $2.50
• 52-Week Range: $1.13 to $2.89
• Volume: 429,950 shs
• Average Volume: 333,252 shs
• Market Capitalization: $88.91 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.67
• Consensus Rating: Moderate Buy

Pulmonx Stock Analysis - MarketRank™

Pulmonx scored higher than 53% of companies evaluated by MarketBeat, and ranked 268th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Pulmonx has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Pulmonx has a consensus price target of $7.67, representing about 270.4% upside from its current price of $2.07.

Amount of Analyst Coverage

Pulmonx has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Pulmonx are expected to grow in the coming year, from ($1.05) to ($0.94) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pulmonx is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pulmonx is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pulmonx has a P/B Ratio of 1.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.46% of the float of Pulmonx has been sold short.

Short Interest Ratio / Days to Cover

Pulmonx has a short interest ratio ("days to cover") of 2.58, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pulmonx has recently decreased by 8.47%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pulmonx does not currently pay a dividend.

Dividend Growth

Pulmonx does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Pulmonx this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Pulmonx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $177,048.00 in company stock.

Percentage Held by Insiders

7.50% of the stock of Pulmonx is held by insiders.

Percentage Held by Institutions

91.04% of the stock of Pulmonx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/29/2026
• Today: 9/20/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:LUNG
• CIK: 1127537
• Web: pulmonx.com
• Phone: 1-650-364-0400
• Fax: N/A
• Employees: 296
• Year Founded: 1998

Price Target and Rating

• Average Price Target for Pulmonx: $7.67
• High Price Target: $14.00
• Low Price Target: $4.00
• Potential Upside/Downside: +270.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$54 million
• Net Margins: -55.03%
• Pretax Margin: -54.35%
• Return on Equity: -96.66%
• Return on Assets: -38.32%

Debt

• Debt-to-Equity Ratio: 0.95
• Current Ratio: 4.32
• Quick Ratio: 3.52

Sales & Book Value

• Annual Sales: $90.50 million
• Price / Sales: 0.98
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.31 per share
• Price / Book: 1.58

Miscellaneous

• Outstanding Shares: 42,950,000
• Free Float: 39,727,000
• Market Cap: $88.91 million
• Optionable: Optionable
• Beta: 0.34